A clinical trial for advanced lung cancer that could incorporate up to 14 different drugs tested in parallel will open later this year under a partnership between Cancer Research UK (CR UK) and two pharmaceutical companies, AstraZeneca (AZ) and Pfizer.
Read MoreUS-based early-development specialist Vince & Associates Clinical Research has broken ground on a US$5 million expansion of its research campus in Overland Park, Kansas.
Read MoreNew York-based private equity firm Arsenal Capital Partners has built on its acquisition of drug discovery, development and safety consultancy Certara last December by snapping up Synchrogenix, a contract research organisation (CRO) specialising in regulatory writing and related services.
Read MorePharmaceutical companies are introducing business planning at an earlier stage of clinical development and exploring statistical models and other predictive tools in an effort to boost the strike rate of new drug candidates, discussions among R&D leaders suggest.
Read MoreCROMSOURCE, the international contract research organisation (CRO) formed from the acquisition of Belgium’s MSOURCE by Italian company CROM in April 2011, has expanded its European headquarters by opening a new office building in Verona, Italy.
Read More
